Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. (Cellerant) is a privately held biotechnology company that is engaged in the development of innovative therapeutics for regulation of the hematopoietic system. The company currently develops cell-based medicine for chemotherapy and radiation induced neutropenia and acute radiation syndrome. Cellerant develops its lead product candidate, CLT-008 as a cell-based medicine for treating neutropenia caused by chemotherapy or radiation exposure and acute radiation syndrome. The company is also applying its expertise in hematopoietic ontogeny in order to indentify therapeutic antibodies and novel drug targets for cancer stem cells. Cellerant was earlier known as Celtrans, LLC. The company is headquartered at San Carlos in California, the US.